Company Profile
NewAmsterdam Pharma Stock Price, News & Analysis
- Ticker:
- NAMS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Stock performance
27.67 USD (+0.91%)
Close
Last updated: August 6, 2026
3.71B USD
Market cap
Why the stock is moving
The latest monitored company update is “NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Oral Lipid-Lowering Therapies
NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol.
Obicetrapib
Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering therapy.
Fixed-Dose Combination
NewAmsterdam is also developing obicetrapib as a fixed-dose combination with ezetimibe, pairing two oral mechanisms in a single tablet.
Phase 3 Program
The BROADWAY, BROOKLYN, TANDEM, PREVAIL, REMBRANDT and RUBENS studies evaluate lipid lowering and cardiovascular outcomes across broad and genetically defined patient populations.
Future catalysts
Regulatory decisions in the European Union, United Kingdom and Switzerland in the second half of 2026.
Topline Phase 3 RUBENS data by year-end 2026.
Potential launches by Menarini in Germany and the United Kingdom in the fourth quarter of 2026, subject to approval.
Recent news
- 01
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: NewAmsterdam Pharma
- 02
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Source: NewAmsterdam Pharma
- 03
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
Source: NewAmsterdam Pharma
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NewAmsterdam Pharma (NAMS)?
NewAmsterdam Pharma (NAMS) most recently closed at 27.67 USD, a +0.91% move versus the previous session.
What is the market cap of NewAmsterdam Pharma (NAMS)?
NewAmsterdam Pharma currently has a market capitalization of 3.71B USD on BioPharmSignal.
What does NewAmsterdam Pharma do?
Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol. Obicetrapib Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering therapy. Fixed-Dose...
On which exchange is NAMS stock listed?
NewAmsterdam Pharma (NAMS) is associated with NASDAQ, Netherlands, Biopharma.
What is Oral?
Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease.
Which conditions is NewAmsterdam Pharma targeting with Oral?
NewAmsterdam Pharma is associated with cardiovascular disease, genetic disease based on its company overview and current catalyst commentary.
How does NewAmsterdam Pharma describe recent progress with Oral?
Regulatory decisions in the European Union, United Kingdom and Switzerland in the second half of 2026. Topline Phase 3 RUBENS data by year-end 2026. Potential launches by Menarini in Germany and the United Kingdom in the fourth quarter of 2026, subject to approval.
What is Lipid-Lowering?
Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease.